TORONTO, April 16, 2019 /PRNewswire/ - VERDEMED HOLDINGS INC. ("Verdemed" or the "Company") proudly announces its sponsorship of the 3rd Benzinga Cannabis Capital Conference, taking place on April 17 and 18, 2019, at the Fairmont Royal York in Toronto.
The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America, connecting entrepreneurs hoping to build billion-dollar cannabis enterprises with investors whose capital can help make that happen.
José Bacellar, President and CEO of Verdemed, will participate in the April 17 opening remarks at the Regional Spotlight – A Look into Latin American Opportunities session. In addition, the Company would like to invite investors interested in becoming better acquainted with Verdemed to attend its April 18 presentation at 1:40 pm in the British Columbia Room.
For more information, please visit www.verdemed.com
President and CEO
Verdemed is a Canadian medical cannabis company working to improve the health of millions of patients in Latin America. Based in Toronto, Verdemed's multi-level and multi-market approach seeks to bridge the gap between the pharmaceutical and medical cannabis landscapes in Europe and North America and the clinical needs of patients and doctors in Latin America.
The Company's international footprint provides strategic access to both familiar and effective cannabis therapies and novel and innovative new products. Verdemed plans to offer a wide range of cannabinoid-based medications to Latin America in the coming years, and expects these products to be fully approved by the regulatory agencies in the region, such as ANMAT, Anvisa, COFEPRIS, DIGEMID, Invima and ISP.
With its Canadian-based products, Verdemed is uniquely positioned to address the high Latin American regulatory hurdles. The Company aspires to become the platform of choice for global innovators seeking to enter Latin America with new medical cannabis products.
Verdemed combines Canadian cannabis industry expertise with smart Latin American capital, general pharmaceutical business knowledge, superior regulatory affairs capabilities and top-tier medical experience.
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause actual results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statements, forward-looking information or financial outlook that are incorporated by reference herein, except as required by applicable securities laws.
SOURCE Verdemed Holdings Inc.